Beta-receptor blocking agents are considered a well defined class of drugs for treating hypertension and heart failure. Nebivolol, a third-generation beta-blocker that combines marked beta-1-receptor selectivity with a vasodilator and antioxidant effect, has relatively recently become available in Hungary. The vasodilator effect of nebivolol has proved to be mediated by the endothelial NO pathway. Due to its neutral metabolic effect, nebivolol can safely be used in patients with glucose intolerance or lipid disorder. Nebivolol is a safe and well tolerated antihypertensive agent. Based on the results of recent clinical trials, nebivolol is also indicated for the treatment of heart failure.
|Number of pages||5|
|Journal||Lege Artis Medicinae|
|Publication status||Published - Dec 1 2006|
ASJC Scopus subject areas